Choose Your Country or Region

Anti-Phospho-Tau (Ser202) Rabbit Antibody [L24P20]

Catalog No.: F4113

Application: Reactivity: Mouse, Rat, Human

Usage Information

Dilution
WB1:1000

Application
WB

Reactivity
Mouse, Rat, Human

Source
Rabbit

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW
50-80 kDa

Datasheet & SDS

Biological Description

Specificity
Anti-Phospho-Tau (Ser202) Rabbit Antibody [L24P20] recognizes endogenous levels of Tau protein only when phosphorylated at Ser202.

Clone
L24P20

Synonym(s)
Microtubule-associated protein tau, Neurofibrillary tangle protein, Paired helical filament-tau (PHF-tau), MAPT , MAPTL, MTBT1, TAU

Background
Tau is a well-characterized microtubule-associated protein predominantly expressed in neurons. Under pathological conditions, tau undergoes abnormal aggregation into insoluble fibrils, a process that contributes to synaptic impairment and neuronal death in a group of neurodegenerative disorders collectively known as tauopathies. The human MAPT gene, located on chromosome 17, encodes tau. In the central nervous system (CNS), tau is synthesized from a 6-kb mRNA transcript that undergoes alternative splicing of exons 2, 3, and 10, giving rise to six distinct isoforms ranging from 37–46 kDa. Tau expression is developmentally regulated. In the fetal brain, only the shortest isoform (0N3R) is expressed, whereas in the adult human brain, all six isoforms are present, with the cerebral cortex containing roughly equal levels of 3R and 4R tau. These isoforms differ in the presence of amino-terminal inserts and the number of tandem repeats near the C-terminus. Tau is subject to extensive phosphorylation, with ~25 phosphorylation sites targeted by kinases such as Erk, glycogen synthase kinase-3 (GSK-3), and CDK5. Phosphorylation reduces tau’s affinity for microtubules, impairing its stabilizing function. One of the defining neuropathological features of Alzheimer’s disease (AD) is the presence of neurofibrillary tangles, composed of paired helical filaments (PHFs) formed by hyperphosphorylated tau. Notably, phosphorylation of tau at Ser396 by GSK-3 or CDK5 disrupts microtubule stability and promotes filament formation, contributing to disease progression.

Background

Tau is a well-characterized microtubule-associated protein predominantly expressed in neurons. Under pathological conditions, tau undergoes abnormal aggregation into insoluble fibrils, a process that contributes to synaptic impairment and neuronal death in a group of neurodegenerative disorders collectively known as tauopathies. The human MAPT gene, located on chromosome 17, encodes tau. In the central nervous system (CNS), tau is synthesized from a 6-kb mRNA transcript that undergoes alternative splicing of exons 2, 3, and 10, giving rise to six distinct isoforms ranging from 37–46 kDa. Tau expression is developmentally regulated. In the fetal brain, only the shortest isoform (0N3R) is expressed, whereas in the adult human brain, all six isoforms are present, with the cerebral cortex containing roughly equal levels of 3R and 4R tau. These isoforms differ in the presence of amino-terminal inserts and the number of tandem repeats near the C-terminus. Tau is subject to extensive phosphorylation, with ~25 phosphorylation sites targeted by kinases such as Erk, glycogen synthase kinase-3 (GSK-3), and CDK5. Phosphorylation reduces tau’s affinity for microtubules, impairing its stabilizing function. One of the defining neuropathological features of Alzheimer’s disease (AD) is the presence of neurofibrillary tangles, composed of paired helical filaments (PHFs) formed by hyperphosphorylated tau. Notably, phosphorylation of tau at Ser396 by GSK-3 or CDK5 disrupts microtubule stability and promotes filament formation, contributing to disease progression.

References
https://pubmed.ncbi.nlm.nih.gov/28386764/

Reference Table for Selecting PVDF Membrane Pore Size Specifications

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%